Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting

Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p.m. Eastern Time Proxies have been mailed to stockholders of record as of the close of business on April 20, 2026; contact information is included below to request additional copies GARDEN CITY, N.Y.

GlobeNewsWire • Jun 10, 2026

Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request to continue its listing on The Nasdaq Stock Market, subject to regaining compliance with the Nasdaq Stock Market LLC's (“Nasdaq” or the “Exchange”) Listing Rule 5550(a)(2) (the “Bid Price Rule”) by July 31, 2026.

GlobeNewsWire • Jun 1, 2026

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

Updated AACR poster data show continued survival follow-up in heavily pre ‑ treated patients following a single intratumoral UNO injection

GlobeNewsWire • Apr 20, 2026

Beyond Air to Participate in the D. Boral Capital Global Conference 2026

GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that Robert Goodman, Chief Executive Officer, and Dan Moorhead, Chief Financial Officer of Beyond Air, will participate in the D. Boral Capital Global Conference 2026, which is being held on Thursday, May 7th, at The Plaza Hotel in New York.

GlobeNewsWire • Apr 15, 2026

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19th Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19th

GlobeNewsWire • Mar 17, 2026

Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today commented on the publication of an independent review article providing the most comprehensive overview to date of high‑dose inhaled nitric oxide (iNO) delivered at concentrations well above the FDA‑approved 20 ppm, and presenting mounting evidence that high‑dose iNO may function as a novel broad‑spectrum antimicrobial therapy for a wide range of respiratory infections. Titled “The therapeutic potential of high‑dose inhaled nitric oxide for antimicrobial effects: a narrative review and future directions,” the article was published in Intensive Care Medicine Experimental (ICMx), a peer-reviewed, open-access journal of the European Society of Intensive Care Medicine, published by Springer Nature Switzerland AG.

GlobeNewsWire • Feb 20, 2026

Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript

Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript

Seeking Alpha • Feb 13, 2026

Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash and marketable securities, including net proceeds from recent PIPE transaction, expected to provide runway into calendar 2027 Signed binding letter of intent for XTL Biopharmaceuticals to acquire 85% of Beyond Air's subsidiary NeuroNOS; Beyond Air to receive up to $32.5 million from the combination of upfront cash, development and commercial milestones and 19.99% equity ownership in XTL Biopharmaceuticals Phase 1a data from UNO program in solid tumors to be presented at AACR Annual Meeting in April 2026 Conference call at 8:00 a.m. ET today, February 13 th    GARDEN CITY, N.Y.

GlobeNewsWire • Feb 13, 2026

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve the lives of patients, today announced that Steve Lisi, Chairman & Chief Executive Officer of Beyond Air, will participate in the 13th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held February 9th to 11th in Snowbird, UT and the Noble Capital Markets Emerging Growth Virtual Equity Conference being held February 4th to 5th.

GlobeNewsWire • Jan 27, 2026

XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma Platform targets the core biology of autism, not just symptomatic relief Beyond Air (NASDAQ: XAIR), majority owner of NeuroNOS, to hold 19.99% of XTL's post-transaction share capital Beyond Air to receive up to $32.5 million in upfront, development and commercial milestone payments TEL AVIV and BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd.

GlobeNewsWire • Jan 13, 2026